Results 111 to 120 of about 53,817 (192)

Peptide Thioester and Triazole Derivatives Through On‐Resin Dual‐Modification of Peptide Thiosulfonates

Angewandte Chemie International Edition, Volume 65, Issue 38, 14 September 2026.
An on‐resin dual‐modification strategy for peptides is presented, comprising S‐alkynylation of peptide thiosulfonates and regioselective iridium‐catalyzed azide–thioalkyne cycloaddition. This method reliably provides access to peptides with intricate non‐canonical modifications, being compatible with complex peptides, alkynes and azides.
Marius Werner, Agnes Bergmann, Chenxi Liu, Mira Behnam, Christian Klein, Franziska Thomas   +5 more
wiley   +1 more source

Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma

, 2013
Hongqing Zhuang,1–4 Zhiyong Yuan,1–4 Jun Wang,1–4 Lujun Zhao,1–4 Qingsong Pang,1–4 Ping Wang1–41Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, 2National Clinical Research Center ...
Zhao L, Wang P, Pang Q, Zhuang H, Wang J, Yuan Z   +5 more
core  

Summary of thirteen patients acquired resistance to erlotinib.

, 2013
Time on erlotinib*, Time to progression after erlotinib therapy; Response#, Response to erlotinib; del,deletion; Adeno, adenocarcinoma. CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.
Xiaoju Zhang (387133), Xitao Ma (387136), Qiyu Qian (387135), Zhaogang Dong (146628), Yi Kang (387134), Guangzhi Liu (294879)   +5 more
core   +1 more source

Four Cases of Interstitial Lung Disease Induced by Erlotinib 
and A Review of the Literatures

Chinese Journal of Lung Cancer, 2012
Erlotinib is an agent of oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors which are used for non-small cell lung cancer. Although this class of agents is considered to be relatively safe, the most serious, but rare, adverse ...
Xiaoling WU, Guanghui GAO, Shengxiang REN, Caicun ZHOU   +3 more
doaj   +1 more source

Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

, 2016
Dolores Isla,1 Javier De Castro,2 Oscar Juan,3 Santiago Grau,4 Javier Orofino,5 Rocío Gordo,5 Carlos Rubio-Terrés,6 Darío Rubio-Rodríguez6 1Medical Oncology Department, Clinical Universitary Hospital Lozano Blesa, Zaragoza ...
De Castro J, Juan O, Rubio-Rodríguez D, Isla D, Orofino J, Rubio-Terrés C, Grau S, Gordo R   +7 more
core  

Erlotinib regulates short-term memory, tau/Aβ pathology, and astrogliosis in mouse models of AD

Frontiers in Immunology
IntroductionErlotinib is an epidermal growth factor receptor (EGFR) inhibitor that is approved by the FDA to treat non-small cell lung cancer (NSCLC). Several membrane receptors, including EGFR, interact with amyloid β (Aβ), raising the possibility that ...
Hyun-ju Lee, Hyun-ju Lee, Jeong-Woo Hwang, Jeong-Woo Hwang, Jieun Kim, A-Ran Jo, A-Ran Jo, Jin-Hee Park, Yoo Joo Jeong, Yoo Joo Jeong, Yoo Joo Jeong, Ji-Yeong Jang, Ji-Yeong Jang, Ji-Yeong Jang, Su-Jeong Kim, Jeong-Heon Song, Hyang-Sook Hoe, Hyang-Sook Hoe, Hyang-Sook Hoe   +18 more
doaj   +1 more source

Pooled Analysis of the Trials of Erlotinib Monotherapy for Epidermal Growth Factor Receptor (EGFR)-mutant Advanced Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2009
Background and objective Erlotinib has been approved worldwide for second- and third-line treatment of advanced NSCLC. Clinical trials showed that patients with EGFR mutations treated with erlotinib has better clinical outcomes.
Li MA, Ting WANG
doaj  

HA/HSA co-modified erlotinib–albumin nanoparticles for lung cancer treatment

, 2018
Yuzhou Shen, Wentao Li Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China Background: Aim of this study was to prepare the hyaluronic acid and human serum albumin modified erlotinib ...
Li W, Shen Y
core  

Time Dependent Inhibition Of CYP3A4 Was The Potent Reason For High-Frequency Clinical Drug-Drug Interaction Of Erlotinib

, 2010
Background: To expain the high frenquency drug-drug interactions of erlotinib, the inhibition potential and kinetic information of erlotinib to seven CYP isoforms was investigated.
张延延, 房中则, 葛广波, Ling Yang, 李巍, 杨凌, 董佩佩, 朱亮亮, 毛玉玺   +8 more
core  

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer.

, 2014
BACKGROUND: Figitumumab (CP-751,871) is a fully human IgG2 monoclonal antibody that inhibits the insulin-like growth factor 1 receptor. This multicenter, randomized, phase III study investigated the efficacy of figitumumab plus erlotinib compared with ...
Hsia, T-C, Blackhall, F; id_orcid, Popat, S, Shepherd, F A, Green, S, Benner, R J, Bondarenko, I, Scagliotti, G V, Sanchez-Torres, J M, Molpus, K, Soria, J-C, Barlesi, F, Jassem, J, Milanowski, J, Novello, S   +14 more
core   +1 more source